Buyout Buzz Boosts Fibrocell Science Stock

FCSC is eyeing its highest close in over a year

Deputy Editor
Sep 13, 2019 at 9:31 AM
facebook twitter linkedin


The shares of Fibrocell Science Inc (NASDAQ:FCSC) are booming on a buyout deal from Castle Creek Pharmaceutical. The privately held company has agreed to acquire Fibrocell Science for about $63.3 million. In response, the penny stock has tacked on 60.1% to trade at $2.93, eyeing its highest close in over a year. 

On the charts, FCSC has been trading between $1.70 and $2.10 for the better part of 2019, with two brief breakouts capped by the stock's 320-day moving average in late March and early April. The stock is trading well atop this trendline today, though it's still well below the all-time high of $862.50, hit back in 2009. 

Only two analysts follow the stock, but both in coverage are extremely bullish, giving FCSC a "buy" or better rating. What's more, the 12-month consensus price target of $15 hasn't been touched by the equity in nearly two years. 

Interestingly enough, short interest just dropped to a one-year low, down 30% in the last two reporting periods. The 518,836 shares sold short still account for a healthy 5.3% of FCSC's available float, however, and would take over two weeks to cover, at the security's average pace of trading. 

 

If you are not making money with options, you aren’t buying options like this…

There is no options strategy that more perfectly approaches trading the fastest moving and most volatile stocks available in the marketplace than this one. In fact, there is no strategy that better utilizes put options for optimal returns and a real trading edge over other traders in the exact same market. New options traders fail out at an incredible rate without proper trade research, execution timing, and option picking. Capitalize on Schaeffer’s 100+ years of options trading excellence with the most coveted product launch in company history. Don't waste another second... join us right now before the next round of trades are released!

Schaeffer's Investment Research Master Portfolio Trial
 


 


 
Special Offers from Schaeffer's Trading Partners